Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Phio Pharmaceuticals Corp. - Common Stock (NQ:PHIO)

1.060 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Phio Pharmaceuticals Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical... 
Via Newsfile
News headline image
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical... 
Via Newsfile
News headline image
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
King of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical... 
Via Newsfile
News headline image
Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision
King of Prussia, Pennsylvania--(Newsfile Corp. - July 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical... 
Via Newsfile
Topics Intellectual Property
News headline image
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - June 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical... 
Via Newsfile
News headline image
Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical... 
Via Newsfile
News headline image
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762
Nitto Denko Avecia begins first commercial-scale cGMP production of PH-762 drug substanceNewly manufactured supply will support upcoming clinical trial in... 
Via Newsfile
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - June 18, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical... 
Via Newsfile
News headline image
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - May 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical... 
Via Newsfile
News headline image
Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026
Live virtual fireside chat — investors, advisors, and life sciences analysts invited to attendFeaturing Dermatologist Mary Spellman, M.D., with Phio... 
Via Newsfile
News headline image
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
Key Development Agreements Secured for Nonclinical Toxicology and U.S. cGMP Clinical Supply ManufacturingKing of Prussia, Pennsylvania--(Newsfile Corp. - May 7,... 
Via Newsfile
News headline image
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - April 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical... 
Via Newsfile
News headline image
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual eventR.... 
Via Newsfile
News headline image
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - April 9, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical... 
Via Newsfile
News headline image
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - March 30, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical... 
Via Newsfile
News headline image
Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement
King of Prussia, Pennsylvania--(Newsfile Corp. - March 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical... 
Via Newsfile
News headline image
Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office
Registration link below for Wednesday March 18, 2026 at 4 PM EDT Phio invites individual and institutional investors, as well... 
Via Newsfile
News headline image
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at... 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT
King of Prussia, Pennsylvania--(Newsfile Corp. - March 10, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical... 
Via Newsfile
News headline image
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update
Treatment Phase for Lead Clinical Candidate PH-762 Dose Escalation Trial is Complete with Favorable Safety, Tolerability and Pathology Data 2025... 
Via Newsfile
News headline image
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Live Presentation and Q&A: Monday, March 9, 2026 10 AM EDTCEO to Discuss INTASYL Platform and PH-762 Phase 1b... 
Via Newsfile
News headline image
Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company
Phase 1b Trial Reported Approximately 65% Pathological Response in cSCC, Including Complete Responses at Maximum Dose, With No Serious Adverse Events 
Via TheNewswire.com
News headline image
Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894
Leadership Enhancements Position Company for Upcoming Regulatory Engagement and Clinical MilestonesNew Appointments Reinforce Operational Readiness Across Finance, Regulatory Affairs and... 
Via Newsfile
Topics Initial Public Offering
Here are the top movers in Wednesday's session. ↗
Via Chartmill
Top movers in Wednesday's session ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.